102
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Characteristics of COPD Phenotypes in Serbia

ORCID Icon, , ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 643-654 | Published online: 16 Mar 2021

References

  • Heffler E, Paoletti G, Giorgis V, et al. Real-life studies of biologics used in asthma patients: key differences and similarities to trials. Expert Rev Clin Immunol. 2019;15(9):951–958. doi:10.1080/1744666X.2019.1653758
  • Bakken IJ, Ariansen AMS, Knudsen GP, Johansen KI, Vollset SE. The norwegian patient registry and the norwegian registry for primary health care: research potential of two nationwide health-care registries. Scand J Public Health. 2020;48(1):49–55. doi:10.1177/1403494819859737
  • Sessa M, Mascolo A, Mortensen RN, et al. Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study. Eur J Heart Fail. 2018;20(3):548–556. doi:10.1002/ejhf.1045
  • Kobayashi S, Hanagama M, Ishida M, et al. Clinical characteristics and outcomes in Japanese patients with COPD according to the 2017 GOLD classification: the Ishinomaki COPD Network Registry. Int J Chron Obstruct Pulmon Dis. 2018;13:3947–3955. doi:10.2147/COPD.S182905
  • Müllerova H, Maselli DJ, Locantore N, et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest. 2015;147(4):999–1007. doi:10.1378/chest.14-0655
  • Vestbo J. COPD: definition and phenotypes. Clin Chest Med. 2014;35(1):1–6. doi:10.1016/j.ccm.2013.10.010
  • Guerreiro I, Soccal PM. COPD and phenotypes. Rev Med Suisse. 2019;15(671):2082–2086.
  • Siafakas N, Corlateanu A, Fouka E. Phenotyping Before Starting Treatment in COPD? COPD. 2017;14(3):367–374. doi:10.1080/15412555.2017.1303041
  • López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirol Carlton Vic. 2016;21(1):14–23. doi:10.1111/resp.12660
  • Lange P, Halpin DM, O’Donnell DE, MacNee W. Diagnosis, assessment, and phenotyping of COPD: beyond FEV1. Int J Chron Obstruct Pulmon Dis. 2016;11(Spec Iss):3–12. doi:10.2147/COPD.S85976
  • Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
  • Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.00102509
  • Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93(3):580–586. doi:10.1378/chest.93.3.580
  • Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53(6):324–335. doi:10.1016/j.arbres.2017.03.018
  • Koblizek V, Milenkovic B, Barczyk A, et al. Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study. Eur Respir J. 2017;49(5):1601446. doi:10.1183/13993003.01446-2016
  • Reiger G, Zwick R, Lamprecht B, Kähler C, Burghuber OC, Valipour A. Phenotypes of COPD in an Austrian population: national data from the POPE study. Wien Klin Wochenschr. 2018;130(11–12):382–389. doi:10.1007/s00508-018-1347-7
  • Alcázar-Navarrete B, Trigueros JA, Riesco JA, Campuzano A, Pérez J. Geographic variations of the prevalence and distribution of COPD phenotypes in Spain: “the ESPIRAL-ES study.”. Int J Chron Obstruct Pulmon Dis. 2018;13:1115–1124. doi:10.2147/COPD.S158031
  • Riesco JA, Alcázar B, Trigueros JA, Campuzano A, Pérez J, Lorenzo JL. Active smoking and COPD phenotype: distribution and impact on prognostic factors. Int J Chron Obstruct Pulmon Dis. 2017;12:1989–1999. doi:10.2147/COPD.S135344
  • Mejza F, Nastałek P, Mastalerz-Migas A, Doniec Z, Skucha W. Coexistence of chronic bronchitis in chronic obstructive lung disease. Adv Exp Med Biol. 2018;1114:1–9.
  • Duffy SP, Criner GJ. Chronic obstructive pulmonary disease: evaluation and management. Med Clin North Am. 2019;103(3):453–461. doi:10.1016/j.mcna.2018.12.005
  • Arkhipov V, Arkhipova D, Miravitlles M, Lazarev A, Stukalina E. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial. Int J Chron Obstruct Pulmon Dis. 2017;12:3255–3262. doi:10.2147/COPD.S142997
  • Chai C-S, Liam C-K, Pang Y-K, et al. Clinical phenotypes of COPD and health-related quality of life: a cross-sectional study. Int J Chron Obstruct Pulmon Dis. 2019;14:565–573. doi:10.2147/COPD.S196109
  • Kania A, Krenke R, Kuziemski K, et al. Distribution and characteristics of COPD phenotypes – results from the Polish sub-cohort of the POPE study. Int J Chron Obstruct Pulmon Dis. 2018;13:1613–1621. doi:10.2147/COPD.S154716
  • Raherison C, Girodet P-O. Epidemiology of COPD. Eur Respir Rev off J Eur Respir Soc. 2009;18(114):213–221. doi:10.1183/09059180.00003609
  • André S, Conde B, Fragoso E, et al. COPD and Cardiovascular Disease. Pulmonology. 2019;25(3):168–176. doi:10.1016/j.pulmoe.2018.09.006
  • Leitao Filho FS, Sin DD. COPD and cardiovascular diseases: now is the time for action! Thorax. 2018;73(9):799–800. doi:10.1136/thoraxjnl-2018-211553
  • Zhou A, Zhou Z, Zhao Y, Chen P. The recent advances of phenotypes in acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1009–1018. doi:10.2147/COPD.S128604
  • Palmiotti GA, Lacedonia D, Liotino V, et al. Adherence to GOLD guidelines in real-life COPD management in the Puglia region of Italy. Int J Chron Obstruct Pulmon Dis. 2018;13:2455–2462. doi:10.2147/COPD.S157779
  • Brown KE, Johnson KJ, DeRonne BM, Parenti CM, Rice KL. Order set to improve the care of patients hospitalized for an exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2016;13(6):811–815. doi:10.1513/AnnalsATS.201507-466OC